Dong Wu

816 total citations
39 papers, 545 citations indexed

About

Dong Wu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Dong Wu has authored 39 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 17 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Dong Wu's work include Acute Myeloid Leukemia Research (21 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Dong Wu is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Dong Wu collaborates with scholars based in China. Dong Wu's co-authors include Chunkang Chang, Lingyun Wu, Juan Guo, Youshan Zhao, Chengming Fei, Jiying Su, Zheng Zhang, Qi He, Luxi Song and Sida Zhao and has published in prestigious journals such as Nature Communications, Blood and PLoS ONE.

In The Last Decade

Dong Wu

34 papers receiving 540 citations

Peers

Dong Wu
Shihui Ma China
Pierre Hirsch France
Bashar Dabbas United States
Inés Gómez‐Seguí Spain
Ghee Young Kwon South Korea
Brittany A. Woods United States
Yan Su China
Ryan J. Mattison United States
Abd Aziz Ibrahim Japan
Stephen Lim United States
Shihui Ma China
Dong Wu
Citations per year, relative to Dong Wu Dong Wu (= 1×) peers Shihui Ma

Countries citing papers authored by Dong Wu

Since Specialization
Citations

This map shows the geographic impact of Dong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dong Wu more than expected).

Fields of papers citing papers by Dong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dong Wu. The network helps show where Dong Wu may publish in the future.

Co-authorship network of co-authors of Dong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Dong Wu. A scholar is included among the top collaborators of Dong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dong Wu. Dong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Guo, Juan, Feng Xu, Jianan Chen, et al.. (2024). The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus. Journal of Cancer Research and Clinical Oncology. 150(2). 71–71. 6 indexed citations
4.
Guo, Juan, Sida Zhao, Lei Shi, et al.. (2024). Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes. European Journal of Pharmacology. 985. 177086–177086.
5.
Zhao, Youshan, Zijuan Li, Juan Guo, et al.. (2023). S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression. Acta Biochimica et Biophysica Sinica. 55(2). 194–201. 3 indexed citations
6.
Zhao, Youshan, et al.. (2023). Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes. Leukemia & lymphoma. 65(1). 100–108. 1 indexed citations
7.
Fang, Ying, Juan Guo, Dong Wu, et al.. (2021). Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome. Frontiers in Oncology. 10. 610525–610525. 4 indexed citations
8.
Li, Xiao, Feng Xu, Zheng Zhang, et al.. (2021). Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Clinical Epigenetics. 13(1). 169–169. 4 indexed citations
9.
Guo, Juan, Youshan Zhao, Zheng Zhang, et al.. (2021). AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance. Acta Biochimica et Biophysica Sinica. 53(4). 492–500. 5 indexed citations
10.
11.
Zhang, Shengyu, Dong Wu, Qiang Wang, et al.. (2018). Clinical characteristics of colonoscopic perforation and risk factors for complications after operational therapy. Zhonghua xiaohua neijing zazhi. 35(7). 465–469. 1 indexed citations
12.
Zheng, Qingqing, Youshan Zhao, Juan Guo, et al.. (2018). Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway. Cell Death and Disease. 9(5). 515–515. 93 indexed citations
13.
Wu, Dong, Yao Zhang, Youshan Zhao, Juan Guo, & Chunkang Chang. (2017). [Inhibitory Effect of Decitabine on Proliferation of MDS-L Cells and Its Mechanism].. PubMed. 25(5). 1471–1476. 1 indexed citations
14.
Xu, Feng, Lingyun Wu, Qi He, et al.. (2017). Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Scientific Reports. 7(1). 43113–43113. 34 indexed citations
15.
Wu, Lingyun, Wenhui Shi, Xiao Li, et al.. (2016). High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. Journal of Translational Medicine. 14(1). 66–66. 18 indexed citations
16.
17.
Xu, Feng, Qi He, Xiao Li, et al.. (2014). Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Scientific Reports. 4(1). 7310–7310. 22 indexed citations
18.
19.
Deng, Jing, et al.. (2011). Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer. Medical Oncology. 29(2). 595–599. 3 indexed citations
20.
Song, Li, Dayi Hu, Hongbing Yan, et al.. (2008). Influence of ambulance use on early reperfusion therapies for acute myocardial infarction. Chinese Medical Journal. 121(9). 771–775. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shihui Ma Breakdown of academic impact, for papers by Pierre Hirsch Breakdown of academic impact, for papers by Bashar Dabbas Breakdown of academic impact, for papers by Inés Gómez‐Seguí Breakdown of academic impact, for papers by Ghee Young Kwon Breakdown of academic impact, for papers by Brittany A. Woods Breakdown of academic impact, for papers by Yan Su Breakdown of academic impact, for papers by Ryan J. Mattison Breakdown of academic impact, for papers by Abd Aziz Ibrahim Breakdown of academic impact, for papers by Stephen Lim
Rankless by CCL
2026